257 related articles for article (PubMed ID: 30354448)
1. Will COMPASS Point to a New Direction in Thrombotic Risk Reduction in Patients With Stable Cardiovascular Disease?
Boden WE; Bhatt DL
Circulation; 2018 Aug; 138(9):858-860. PubMed ID: 30354448
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease.
Liang Y; Zhu J; Liu L; Anand SS; Connolly SJ; Bosch J; Guzik TJ; O'Donnell M; Dagenais GR; Fox KA; Shestakovska O; Berkowitz SD; Muehlhofer E; Keller L; Yusuf S; Eikelboom JW;
Cardiovasc Res; 2021 Feb; 117(3):942-949. PubMed ID: 32289159
[TBL] [Abstract][Full Text] [Related]
3. Rivaroxaban in peripheral artery disease: The new kid on the block?
Hussain MA; Verma S; Al-Omran M
J Vasc Surg; 2018 Mar; 67(3):985-986. PubMed ID: 29477208
[No Abstract] [Full Text] [Related]
4. Fighting residual cardiovascular risk in stable patients with atherosclerotic vascular disease: COMPASS in context.
Patrono C
Cardiovasc Res; 2017 Dec; 113(14):e61-e63. PubMed ID: 29186439
[No Abstract] [Full Text] [Related]
5. Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin.
Eikelboom JW; Bosch JJ; Connolly SJ; Shestakovska O; Dagenais GR; Hart RG; Leong DP; O'Donnell M; Fox KAA; Bhatt DL; Cairns JA; Tasto C; Berkowitz SD; Cook Bruns N; Muehlhofer E; Diaz R; Maggioni AP; Yusuf S
J Am Coll Cardiol; 2019 Sep; 74(12):1519-1528. PubMed ID: 31537259
[TBL] [Abstract][Full Text] [Related]
6. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Connolly SJ; Eikelboom JW; Bosch J; Dagenais G; Dyal L; Lanas F; Metsarinne K; O'Donnell M; Dans AL; Ha JW; Parkhomenko AN; Avezum AA; Lonn E; Lisheng L; Torp-Pedersen C; Widimsky P; Maggioni AP; Felix C; Keltai K; Hori M; Yusoff K; Guzik TJ; Bhatt DL; Branch KRH; Cook Bruns N; Berkowitz SD; Anand SS; Varigos JD; Fox KAA; Yusuf S;
Lancet; 2018 Jan; 391(10117):205-218. PubMed ID: 29132879
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban (Xarelto) plus aspirin for secondary prevention of cardiovascular events.
Med Lett Drugs Ther; 2018 Dec; 60(1561):196-197. PubMed ID: 30653475
[No Abstract] [Full Text] [Related]
8. Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial.
Vanassche T; Verhamme P; Anand SS; Shestakovska O; Fox KA; Bhatt DL; Avezum A; Alings M; Aboyans V; Maggioni AP; Widimsky P; Berkowitz SD; Yusuf S; Connolly SJ; Eikelboom JW; Bosch J
Eur J Prev Cardiol; 2020 Feb; 27(3):296-307. PubMed ID: 31615291
[TBL] [Abstract][Full Text] [Related]
9. Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease.
Eikelboom JW; Bhatt DL; Fox KAA; Bosch J; Connolly SJ; Anand SS; Avezum A; Berkowitz SD; Branch KRH; Dagenais GR; Félix C; Guzik TJ; Hart RG; Maggioni AP; Muehlhofer E; Sharma M; Shestakovska O; Yusuf S
J Am Coll Cardiol; 2021 Jul; 78(1):14-23. PubMed ID: 34210409
[TBL] [Abstract][Full Text] [Related]
10. Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease.
Branch KR; Probstfield JL; Eikelboom JW; Bosch J; Maggioni AP; Cheng RK; Bhatt DL; Avezum A; Fox KAA; Connolly SJ; Shestakovska O; Yusuf S
Circulation; 2019 Aug; 140(7):529-537. PubMed ID: 31163978
[TBL] [Abstract][Full Text] [Related]
11. The evolving treatment of peripheral arterial disease: preventing ischaemic events in the post-COMPASS era.
Kaplovitch E; Anand SS
Cardiovasc Res; 2019 Oct; 115(12):e121-e124. PubMed ID: 31321405
[No Abstract] [Full Text] [Related]
12. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.
Moayyedi P; Eikelboom JW; Bosch J; Connolly SJ; Dyal L; Shestakovska O; Leong D; Anand SS; Störk S; Branch KRH; Bhatt DL; Verhamme PB; O'Donnell M; Maggioni AP; Lonn EM; Piegas LS; Ertl G; Keltai M; Bruns NC; Muehlhofer E; Dagenais GR; Kim JH; Hori M; Steg PG; Hart RG; Diaz R; Alings M; Widimsky P; Avezum A; Probstfield J; Zhu J; Liang Y; Lopez-Jaramillo P; Kakkar AK; Parkhomenko AN; Ryden L; Pogosova N; Dans AL; Lanas F; Commerford PJ; Torp-Pedersen C; Guzik TJ; Vinereanu D; Tonkin AM; Lewis BS; Felix C; Yusoff K; Metsarinne KP; Fox KAA; Yusuf S;
Gastroenterology; 2019 Sep; 157(3):682-691.e2. PubMed ID: 31152740
[TBL] [Abstract][Full Text] [Related]
13. Patients with Peripheral Artery Disease in the COMPASS Trial.
Kruger PC; Anand SS; de Vries TAC; Eikelboom JW
Eur J Vasc Endovasc Surg; 2018 Dec; 56(6):772-773. PubMed ID: 30213508
[No Abstract] [Full Text] [Related]
14. Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial.
Anand SS; Caron F; Eikelboom JW; Bosch J; Dyal L; Aboyans V; Abola MT; Branch KRH; Keltai K; Bhatt DL; Verhamme P; Fox KAA; Cook-Bruns N; Lanius V; Connolly SJ; Yusuf S
J Am Coll Cardiol; 2018 May; 71(20):2306-2315. PubMed ID: 29540326
[TBL] [Abstract][Full Text] [Related]
15. Rivaroxaban 2.5 mg. No justification for using this anticoagulant after an acute coronary syndrome.
Prescrire Int; 2014 Oct; 23(153):229-32. PubMed ID: 25964962
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective.
Zomer E; Si S; Hird TR; Liew D; Owen AJ; Tonkin A; Reid CM; Ademi Z
Eur J Prev Cardiol; 2019 May; 26(8):858-868. PubMed ID: 30526023
[TBL] [Abstract][Full Text] [Related]
17. Optimizing the Safe Use of Direct Oral Anticoagulants in Older Patients: A Teachable Moment.
Sennesael AL; Dogné JM; Spinewine A
JAMA Intern Med; 2015 Oct; 175(10):1608-9. PubMed ID: 26237648
[No Abstract] [Full Text] [Related]
18. Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials.
Anand SS; Hiatt W; Dyal L; Bauersachs R; Berkowitz SD; Branch KRH; Debus S; Fox KAA; Liang Y; Muehlhofer E; Nehler M; Haskell LP; Patel M; Szarek M; Yusuf S; Eikelboom J; Bonaca MP
Eur J Prev Cardiol; 2022 May; 29(5):e181-e189. PubMed ID: 34463737
[TBL] [Abstract][Full Text] [Related]
19. The impact of low-dose anticoagulation therapy on peripheral artery disease: insights from the VOYAGER trial.
Fukaya E; Leeper NJ
Cardiovasc Res; 2020 Oct; 116(12):e156-e158. PubMed ID: 32980875
[No Abstract] [Full Text] [Related]
20. Triple therapy: worth the risk?
Wernly B; Lichtenauer M; Hoppe UC; Lauten A; Navarese EP; Jung C
Minerva Med; 2018 Oct; 109(5):403-405. PubMed ID: 30338683
[No Abstract] [Full Text] [Related]
[Next] [New Search]
